Scholarlink

Background <p>Fibrotic lung diseases are part of the large and heterogeneous group of interstitial lung diseases (ILD), which are characterized by a&#xa0;progressive fibrotic remodelling of alveolar lung parenchyma.</p> Objective <p>Overview of the spectrum of fibrotic lung diseases.</p> Material and methods <p>A literature search was carried out in the PubMed and MEDLINE database.</p> Results <p>The etiology of fibrotic ILD is diverse and includes inhaled exogenous noxious substances (dust, gases), infections, drug reactions, ionizing radiation and endogenous autoimmune or rare genetically determined metabolic and storage disorders; however, the etiology of some ILDs, so-called idiopathic interstitial pneumonia (IIP), is not fully understood although environmental pollution, tobacco smoke and genetic polymorphisms have been identified as risk factors. The most important and best studied representative of IIP is idiopathic pulmonary fibrosis (IPF). The diagnosis of ILD is complex and requires an interdisciplinary approach taking the clinical presentation, radiological patterns, and possibly bronchoalveolar lavage and histological findings into account. Characteristic of progressive fibrotic lung disease is progressive fibrotic tissue remodeling, which is manifested as clinical, functional and radiological deterioration and is referred to as progressive pulmonary fibrosis (PPF). Antifibrotic drugs delay the progression of IPF and PPF but are not curative.</p> Discussion <p>In addition to early diagnosis and preventive strategies, a&#xa0;better understanding of the causes of fibrotic ILD is required in order to avoid triggering noxious agents, identify dysregulated signalling pathways and develop targeted treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Zielorgan Lunge: Vielfalt der fibrotischen Lungenerkrankungen

  • 期刊论文

  • 发表日期：

    2025年6月24日

查看全文
  • Gabriela Leuschner,
  • Jürgen Behr

摘要

Background

Fibrotic lung diseases are part of the large and heterogeneous group of interstitial lung diseases (ILD), which are characterized by a progressive fibrotic remodelling of alveolar lung parenchyma.

Objective

Overview of the spectrum of fibrotic lung diseases.

Material and methods

A literature search was carried out in the PubMed and MEDLINE database.

Results

The etiology of fibrotic ILD is diverse and includes inhaled exogenous noxious substances (dust, gases), infections, drug reactions, ionizing radiation and endogenous autoimmune or rare genetically determined metabolic and storage disorders; however, the etiology of some ILDs, so-called idiopathic interstitial pneumonia (IIP), is not fully understood although environmental pollution, tobacco smoke and genetic polymorphisms have been identified as risk factors. The most important and best studied representative of IIP is idiopathic pulmonary fibrosis (IPF). The diagnosis of ILD is complex and requires an interdisciplinary approach taking the clinical presentation, radiological patterns, and possibly bronchoalveolar lavage and histological findings into account. Characteristic of progressive fibrotic lung disease is progressive fibrotic tissue remodeling, which is manifested as clinical, functional and radiological deterioration and is referred to as progressive pulmonary fibrosis (PPF). Antifibrotic drugs delay the progression of IPF and PPF but are not curative.

Discussion

In addition to early diagnosis and preventive strategies, a better understanding of the causes of fibrotic ILD is required in order to avoid triggering noxious agents, identify dysregulated signalling pathways and develop targeted treatment.